ROL' AL'DOSTERONA V PORAZhENII POChEK PRI METABOLIChESKOM SINDROME, ASSOTsIIROVANNOM S OZhIRENIEM
- Authors: Kutyrina IM1, Kryachkova AA1, Savel'eva SA1, Shestakova MV1
-
Affiliations:
- Issue: No 4 (2010)
- Pages: 34-44
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245887
- ID: 245887
Cite item
Full Text
Abstract
Aim of the study. To determine role of aldosterone in chronic kidney disease development in metabolic syndrome, associated with obesity.
Materials and methods. 79 patients with metabolic syndrome (64,6% male, 35,4% female, age 36 - 58 years) were included into the study. All patients were divided into 3 groups: 1st with body mass index (BMI) 25,0-29,9 kg/m², 2nd - with BMI 30,0-39,9 kg/m², 3rd - третья - с with BMI >40,0 kg/m². In al patients microalbuminuria, plasma renin activity and aldosterone concentration, insulin and HOMA-insulinoresistance (HОМА-IR) were determined.
Результаты. As BMI increased, plasma aldosterone concentration rose independently of plasma renin activity. Plasma aldosterone concentration was directly associated with lipid and glucose metabolism parameters and iverslu associated with glomerular filtration rate. Plasma aldosterone concentration was an independent determinant of microalbuminuria.
Conclusion. Rise of plasma aldosterone concentration is one of the independent risk factor of development of nephropathy, associated with metabolic syndrome and obesity.
Materials and methods. 79 patients with metabolic syndrome (64,6% male, 35,4% female, age 36 - 58 years) were included into the study. All patients were divided into 3 groups: 1st with body mass index (BMI) 25,0-29,9 kg/m², 2nd - with BMI 30,0-39,9 kg/m², 3rd - третья - с with BMI >40,0 kg/m². In al patients microalbuminuria, plasma renin activity and aldosterone concentration, insulin and HOMA-insulinoresistance (HОМА-IR) were determined.
Результаты. As BMI increased, plasma aldosterone concentration rose independently of plasma renin activity. Plasma aldosterone concentration was directly associated with lipid and glucose metabolism parameters and iverslu associated with glomerular filtration rate. Plasma aldosterone concentration was an independent determinant of microalbuminuria.
Conclusion. Rise of plasma aldosterone concentration is one of the independent risk factor of development of nephropathy, associated with metabolic syndrome and obesity.
Keywords
References
- Reaven G.M Banting Lecture: role insulin resistance in human disease.Diabetes.1988;37:1595-1607.
- Maison P, Byme CD, Hales CN. Et al.Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care.2001;24:1758-1763.
- Liese A, Mayer-Davis E, Tyroler H. et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Ann. Epidemiol. 1997;7:407-416.
- Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet. 1952;263:226-228.
- Conn JW. Primary aldosteronism: A new clinical syndrome. J. Lab. Clin. Med.1955;45:3-17.
- Conn JW, Knopf RF, Nesbit RM: Clinical characteristics of primary aldosteronism from an analisis of 145 cases. An. J. Surg. 1964;107:159-172.
- Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin. Inverst. 1996; 98:1063-1068
- Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA. et al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cell. Endocr. Res. 2004;30:865-870.
- Nagase M, Yoshida S, Shibata S, Nagase T. Et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat -derived factors. J. Am. Soc.Nephrol. 2006;17:3438-3446
- Krug A. Ehrhart-Bornstein M. Aldosteron and Metabolic Syndrome. Is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension.2008;51:1252-1258.
- Сatena C, Lapenna R, Baroselli S, Nadalini E. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin Endocrinol Metab.2006;91:3457-3463.
- Goodfriend TL, Ball DL, Egan BM. et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358-363
- Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney int.1992;41:326-333.
- Del Vecchio L, Procaccio M, Vigano S, Cusi D. The role of aldosterone in kidney damage and clinical benefits of its blockade. Nat. Clin Pract Nephrol. 2007;3:42-47.
- Eddy AA. Plasminogen activator inhibitor-1 and kidney. Am.J. Physiol Renal Physiol. 2002;283:209-220.
- Quinkler M, Zehnder D, Eardley KS, Lepenies J.Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria.Cerculation. 2005; 112: 1435-1443
- Epstein M. Aldosterone blockade an emerging strategy for abrogating progressive renal disease. Am. J. Med. 2006;119:912-9.
- Epstein M. Williams GH, Weinberger M. Lewin A. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-951.
Supplementary files
